Choudhary and colleagues from the laboratory of Ira Pastan reported the synthesis of the first PE-based MSLN-targeted immunotoxin in 1998, and demonstrated anti-tumor activity in mice bearing human tumors expressing MSLN [37]. Here, MSLN is linked to neoplasm.